These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30730667)

  • 21. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.
    Stauner CT; Drexler K; Berneburg M; Haferkamp S
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577
    [No Abstract]   [Full Text] [Related]  

  • 22. The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
    Hanna DL; Law SJ; Merrick SA; Heptinstall L; Bass P; Dupont P; Sheri A
    Melanoma Res; 2020 Jun; 30(3):321-324. PubMed ID: 31764435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Simetić L; Blažičević K; Međugorac K; Golčić M; Herceg D
    Anticancer Res; 2020 Apr; 40(4):2157-2163. PubMed ID: 32234909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 26. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
    Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 28. The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
    Ladwa R; Atkinson V
    Melanoma Res; 2017 Apr; 27(2):168-170. PubMed ID: 28099369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-transit metastases: the migration of melanoma.
    Pararajasingam A; Goodwin R
    Br J Hosp Med (Lond); 2020 Sep; 81(9):1. PubMed ID: 32990085
    [No Abstract]   [Full Text] [Related]  

  • 30. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    Dagogo-Jack I; Lanfranchi M; Gainor JF; Giobbie-Hurder A; Lawrence DP; Shaw AT; Sullivan RJ
    J Immunother; 2017 Apr; 40(3):108-113. PubMed ID: 28221189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The future of melanoma therapy: developing new drugs and improving the use of old ones.
    Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
    Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
    [No Abstract]   [Full Text] [Related]  

  • 32. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 33. A rapid response to pembrolizumab in a patient with metastatic melanoma.
    Bayo Calero J; Aviñó Tarazona V
    Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
    Igari S; Yamamoto M; Kikuchi N; Ohtsuka M; Yamamoto T
    An Bras Dermatol; 2024; 99(3):450-451. PubMed ID: 38307808
    [No Abstract]   [Full Text] [Related]  

  • 35. Pembrolizumab for Recurrent Conjunctival Melanoma.
    Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
    JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
    [No Abstract]   [Full Text] [Related]  

  • 36. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
    Cimminiello C; Indini A; Di Guardo L; Prisciandaro M; Randon G; Tolomio E; De Braud F; Del Vecchio M
    Melanoma Res; 2019 Jun; 29(3):289-294. PubMed ID: 30520799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversible BRAF inhibitor-induced acute exudative paraneoplastic polymorphous vitelliform maculopathy.
    Samalia P; Niederer R
    N Z Med J; 2021 Aug; 134(1540):89-92. PubMed ID: 34482393
    [No Abstract]   [Full Text] [Related]  

  • 38. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M; Owen JL; Choi JN
    JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
    [No Abstract]   [Full Text] [Related]  

  • 39. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
    Wolner ZJ; Marghoob AA; Pulitzer MP; Postow MA; Marchetti MA
    Br J Dermatol; 2018 Jan; 178(1):265-269. PubMed ID: 28132411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab for primary malignant melanoma of the central nervous system.
    El Habnouni C; Bléchet C; Bens G
    J Neurooncol; 2018 Aug; 139(1):225-227. PubMed ID: 29611049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.